2019 - 2022 Development of therapeutics for lung cancer that target factors stabilizing epithelial-to-mesenchymal transition
Papers (34):
田中 一大, 玄 崇永, 堀 和美, 森瀬 昌宏, 神山 潤二, 小玉 勇太, 松井 彰, 宮沢 亜矢子, 長谷 哲成, 日比野 佳孝, et al. EGFR遺伝子変異を有する非小細胞肺癌患者の骨転移が、オシメルチニブの治療効果に与える影響 多施設共同後ろ向きコホート研究(Prognostic impact of bone metastases in osimertinib-treated patients with EGFR-mutated NSCLC). 日本癌学会総会記事. 2024. 83回. P-1216
Yoshito Imamura, Taketo Kato, Yuji Nomata, Shoji Okado, Hiroki Watanabe, Yuta Kawasumi, Keita Nakanishi, Yuka Kadomatsu, Harushi Ueno, Shota Nakamura, et al. Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer. Anticancer research. 2024. 44. 8. 3451-3461
Taketo Kato, Hironori Oyamatsu, Yuki Hanamatsu, Heng Huang, Shoji Okado, Yoshito Imamura, Yuji Nomata, Hiroki Watanabe, Yuka Kadomatsu, Harushi Ueno, et al. Transcriptomic profiling of a late recurrent nuclear protein in testis carcinoma of the lung 14 years after the initial operation: a case report. Translational Lung Cancer Research. 2024. 13. 7. 1756-1762
Takayuki Owaki, Tadashi Iida, Yuki Miyai, Katsuhiro Kato, Tetsunari Hase, Makoto Ishii, Ryota Ando, Kunihiko Hinohara, Tomohiro Akashi, Yasuyuki Mizutani, et al. Synthetic retinoid-mediated preconditioning of cancer-associated fibroblasts and macrophages improves cancer response to immune checkpoint blockade. British journal of cancer. 2024. 131. 2. 372-386
Tomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, Tetsushi Izuchi, Koji Suzuki, Koki Otake, Yoshinori Yasuda, Masahiko Ando, Takeshi Onoue, Takashi Miyata, et al. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study. Cancer immunology, immunotherapy : CII. 2024. 73. 8. 146-146